

Erik van Werkhoven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1182353/publications.pdf>

Version: 2024-02-01

88
papers

5,892
citations

147801

31
h-index

76900

74
g-index

90
all docs

90
docs citations

90
times ranked

9343
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Oncology</i> , The, 2015, 16, 630-637.	10.7	1,220
2	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019, 25, 920-928.	30.7	589
3	Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	451
4	Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. <i>Investigational New Drugs</i> , 2015, 33, 201-214.	2.6	327
5	Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. <i>Journal of Clinical Oncology</i> , 2016, 34, 4354-4361.	1.6	241
6	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , The, 2018, 19, 1459-1467.	10.7	238
7	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1630-1640.	10.7	237
8	Angiotensin II Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1030.	7.1	160
9	Prognostic Factors for Occult Inguinal Lymph Node Involvement in Penile Carcinoma and Assessment of the High-Risk EAU Subgroup: A Two-Institution Analysis of 342 Clinically Node-Negative Patients. <i>European Urology</i> , 2010, 58, 742-747.	1.9	125
10	Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial. <i>JAMA Oncology</i> , 2017, 3, 42.	7.1	124
11	Contemporary Management of Regional Nodes in Penile Cancer—Improvement of Survival?. <i>Journal of Urology</i> , 2014, 191, 68-73.	0.4	116
12	Human Papillomavirus Prevalence in Invasive Penile Cancer and Association with Clinical Outcome. <i>Journal of Urology</i> , 2015, 193, 526-531.	0.4	102
13	Penile Sparing Surgery for Penile Cancer—Does it Affect Survival?. <i>Journal of Urology</i> , 2014, 192, 120-126.	0.4	99
14	Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. <i>British Journal of Cancer</i> , 2017, 116, 1415-1424.	6.4	94
15	Prognostic Significance of Extranodal Extension in Patients With Pathological Node Positive Penile Carcinoma. <i>Journal of Urology</i> , 2010, 184, 1347-1353.	0.4	89
16	Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial. <i>Radiotherapy and Oncology</i> , 2015, 117, 44-48.	0.6	84
17	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. <i>European Urology Focus</i> , 2019, 5, 857-866.	3.1	67
18	Inguinal Recurrence Following Therapeutic Lymphadenectomy for Node Positive Penile Carcinoma: Outcome and Implications for Management. <i>Journal of Urology</i> , 2011, 185, 888-894.	0.4	66

#	ARTICLE	IF	CITATIONS
19	A cost analysis of upfront DPYD genotypeâ€“guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019, 107, 60-67.	2.8	65
20	Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. <i>Annals of Oncology</i> , 2017, 28, 1288-1293.	1.2	58
21	Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial. <i>Radiotherapy and Oncology</i> , 2011, 100, 101-107.	0.6	54
22	Neoadjuvant Taxane-Based Combination Chemotherapy in Patients With Advanced Penile Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 44-49.	1.9	50
23	Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas. <i>Cancers</i> , 2016, 8, 21.	3.7	50
24	Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial. <i>Radiotherapy and Oncology</i> , 2018, 128, 434-441.	0.6	48
25	Induction Chemotherapy Followed by Surgery in Node Positive Bladder Cancer. <i>Urology</i> , 2014, 83, 134-139.	1.0	46
26	Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: A literature-based critical review. <i>Cancer Treatment Reviews</i> , 2017, 59, 102-108.	7.7	45
27	Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma. <i>JAMA Oncology</i> , 2021, 7, e205865.	7.1	45
28	Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 391-400.	2.5	42
29	Progression of carotid intima media thickness after radiotherapy: A long-term prospective cohort study. <i>Radiotherapy and Oncology</i> , 2014, 113, 359-363.	0.6	39
30	Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database. <i>Gynecologic Oncology</i> , 2019, 152, 361-367.	1.4	39
31	Tumor volume as a prognostic factor for local control and overall survival in advanced larynx cancer. <i>Laryngoscope</i> , 2016, 126, E60-7.	2.0	37
32	Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. <i>Breast</i> , 2016, 29, 153-159.	2.2	31
33	Prophylactic Pelvic Lymph Node Dissection in Patients with Penile Cancer. <i>Journal of Urology</i> , 2015, 193, 1976-1980.	0.4	30
34	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). <i>European Urology</i> , 2019, 75, 261-264.	1.9	30
35	COVID-19 vaccination in patients with immune thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 1637-1644.	5.2	30
36	Implementation of a Multicenter Biobanking Collaboration for Nextâ€“Generation Sequencingâ€“Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. <i>Oncologist</i> , 2017, 22, 33-40.	3.7	29

#	ARTICLE	IF	CITATIONS
37	Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment). <i>Breast</i> , 2018, 40, 76-81.	2.2	29
38	Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 73-79.	5.4	29
39	SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: A potentially practice-changing approach. <i>Radiotherapy and Oncology</i> , 2020, 147, 56-63.	0.6	29
40	Prediction of Acute Toxicity Grade ≥ 3 in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Intensity Modulated Radiotherapy and Concurrent Low-Dose Cisplatin. <i>Clinical Lung Cancer</i> , 2013, 14, 541-548.	2.6	26
41	Prognostic factors in patients with oligometastatic breast cancer – A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 91, 102114.	7.7	24
42	Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. <i>Clinical Cancer Research</i> , 2022, 28, 1402-1411.	7.0	24
43	Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele. <i>International Journal of Cancer</i> , 2016, 138, 245-253.	5.1	23
44	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. <i>European Journal of Cancer</i> , 2017, 74, 47-54.	2.8	21
45	High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases. <i>Clinical and Translational Radiation Oncology</i> , 2020, 20, 45-50.	1.7	21
46	Ultrasound Examination and Fine Needle Aspiration Cytology – Useful for Followup of the Regional Nodes in Penile Cancer?. <i>Journal of Urology</i> , 2014, 191, 652-655.	0.4	20
47	Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1256-1266.	7.0	20
48	Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2013, 109, 2965-2972.	6.4	19
49	An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 567-574.	2.5	18
50	Blood and lymphatic microvessel damage in irradiated human skin: The role of TGF- β 2, endoglin and macrophages. <i>Radiotherapy and Oncology</i> , 2015, 116, 455-461.	0.6	17
51	The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies. <i>Annals of Oncology</i> , 2016, 27, 1638-1643.	1.2	17
52	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6598-6605.	7.0	17
53	Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore. <i>Clinical Cancer Research</i> , 2019, 25, 4985-4992.	7.0	17
54	Association of Image-Guided Navigation With Complete Resection Rate in Patients With Locally Advanced Primary and Recurrent Rectal Cancer. <i>JAMA Network Open</i> , 2020, 3, e208522.	5.9	16

#	ARTICLE	IF	CITATIONS
55	Randomised study of tegafurâ€“uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer â€” TLC study. <i>Journal of Geriatric Oncology</i> , 2015, 6, 307-315.	1.0	15
56	Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial. <i>Radiotherapy and Oncology</i> , 2016, 120, 107-113.	0.6	15
57	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). <i>Scandinavian Journal of Urology</i> , 2019, 53, 14-20.	1.0	15
58	Neutropenia and docetaxel exposure in metastatic castrationâ€“resistant prostate cancer patients: A metaâ€“analysis and evaluation of a clinical cohort. <i>Cancer Medicine</i> , 2019, 8, 1406-1415.	2.8	13
59	The Prognostic Value of Baseline 18F-FDG PET/CT in Human Papillomavirusâ€“Positive Versus Human Papillomavirusâ€“Negative Patients With Oropharyngeal Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e323-e328.	1.3	13
60	Lymph node count at radical cystectomy does not influence long-term survival if surgeons adhere to a standardized template. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 504.e19-504.e24.	1.6	12
61	Penile Cancer Stage, Survival and Body Mass Index. <i>Urologia Internationalis</i> , 2015, 94, 220-224.	1.3	12
62	Prostate sparing cystectomy for bladder cancer: A two-center study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1446-1452.	1.0	12
63	Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer. <i>Breast Journal</i> , 2013, 19, 419-426.	1.0	11
64	Variations in pelvic lymph node dissection in invasive bladder cancer: A Dutch nationwide population-based study during centralization of care. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 532.e7-532.e12.	1.6	11
65	Short-term outcome after cystectomy: comparison of early oral feeding in an enhanced recovery protocol and feeding using Bengmark nasojejunal tube. <i>World Journal of Urology</i> , 2018, 36, 221-229.	2.2	11
66	Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 919-926.	1.3	11
67	Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer. <i>Radiotherapy and Oncology</i> , 2019, 141, 130-136.	0.6	11
68	Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomographyâ€“Should Patients Receive Further Evaluation?. <i>Journal of Urology</i> , 2016, 195, 907-912.	0.4	10
69	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1973-1980.	2.2	10
70	Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survival. <i>World Journal of Urology</i> , 2013, 31, 1297-1302.	2.2	9
71	Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 130, 511-517.	1.4	9
72	Prospective Cohort Study of Carotid Intima-media Thickness after Irradiation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 2701-2707.	1.6	9

#	ARTICLE	IF	CITATIONS
73	Randomized controlled trial to identify the optimal radiotherapy scheme for palliative treatment of incurable head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2020, 149, 181-188.	0.6	9
74	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. <i>Clinical Cancer Research</i> , 2021, 27, 6106-6114.	7.0	9
75	Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. <i>Oncotarget</i> , 2017, 8, 55582-55592.	1.8	9
76	Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer. <i>Current Clinical Pharmacology</i> , 2014, 9, 139-147.	0.6	9
77	Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 113531-113542.	1.8	8
78	Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute. <i>Breast</i> , 2016, 30, 19-25.	2.2	7
79	Effectiveness of a multicentre nasopharyngeal carcinoma awareness programme in Indonesia. <i>BMJ Open</i> , 2016, 6, e008571.	1.9	6
80	Detection of endogenously circulating mesenchymal stem cells in human cancer patients. <i>International Journal of Cancer</i> , 2018, 143, 2516-2524.	5.1	6
81	Endo-Urological Techniques for Benign Uretero-Ileal Strictures Have Poor Efficacy and Affect Renal Function. <i>Urologia Internationalis</i> , 2018, 100, 18-24.	1.3	5
82	Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 171, 114-123.	2.8	5
83	Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival. <i>Breast</i> , 2022, 65, 110-115.	2.2	5
84	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. <i>Clinical Cancer Research</i> , 2022, 28, 960-971.	7.0	4
85	Imaging modalities used for follow-up of localized renal cell carcinoma (RCC) and subsequent effect on overall survival after recurrence: RECUR-database analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 637-637.	1.6	2
86	Redistributed versus homogenous radiotherapy dose for head and neck cancer; a treatment planning study. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 3, 17-20.	2.9	1
87	Always randomize as late as possible. <i>Gastric Cancer</i> , 2019, 22, 1308-1309.	5.3	1
88	Analysis of Contemporary Treatment of Penile Cancer at the Netherlands Cancer Institute. , 2014, , 137-152.		0